Next Article in Journal
The Function of Sialidase Revealed by Sialidase Activity Imaging Probe
Next Article in Special Issue
The Role of Endoglin in Hepatocellular Carcinoma
Previous Article in Journal
T and B Lymphocyte Transcriptional States Differentiate between Sensitized and Unsensitized Individuals in Alpha-Gal Syndrome
Previous Article in Special Issue
Evaluation of a Novel Plasmid for Simultaneous Gene Electrotransfer-Mediated Silencing of CD105 and CD146 in Combination with Irradiation

Endoglin in the Spotlight to Treat Cancer

Microenvironment and Metastasis Group, Department of Molecular Oncology, Spanish National Cancer Research Center (CNIO), 28029 Madrid, Spain
Molecular Pathology of Sarcomas, Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital, CSIC, University of Sevilla, CIBERONC, 41013 Seville, Spain
Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009 Seville, Spain
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors shared senior authorship.
Academic Editors: Lukas J. A. C. Hawinkels and Marie-José Goumans
Int. J. Mol. Sci. 2021, 22(6), 3186;
Received: 22 January 2021 / Revised: 6 March 2021 / Accepted: 17 March 2021 / Published: 20 March 2021
(This article belongs to the Special Issue Endoglin in Health and Disease)
A spotlight has been shone on endoglin in recent years due to that fact of its potential to serve as both a reliable disease biomarker and a therapeutic target. Indeed, endoglin has now been assigned many roles in both physiological and pathological processes. From a molecular point of view, endoglin mainly acts as a co-receptor in the canonical TGFβ pathway, but also it may be shed and released from the membrane, giving rise to the soluble form, which also plays important roles in cell signaling. In cancer, in particular, endoglin may contribute to either an oncogenic or a non-oncogenic phenotype depending on the cell context. The fact that endoglin is expressed by neoplastic and non-neoplastic cells within the tumor microenvironment suggests new possibilities for targeted therapies. Here, we aimed to review and discuss the many roles played by endoglin in different tumor types, as well as the strong evidence provided by pre-clinical and clinical studies that supports the therapeutic targeting of endoglin as a novel clinical strategy. View Full-Text
Keywords: endoglin; tumor; microenvironment; targeted therapy; biomarker endoglin; tumor; microenvironment; targeted therapy; biomarker
Show Figures

Figure 1

MDPI and ACS Style

González Muñoz, T.; Amaral, A.T.; Puerto-Camacho, P.; Peinado, H.; de Álava, E. Endoglin in the Spotlight to Treat Cancer. Int. J. Mol. Sci. 2021, 22, 3186.

AMA Style

González Muñoz T, Amaral AT, Puerto-Camacho P, Peinado H, de Álava E. Endoglin in the Spotlight to Treat Cancer. International Journal of Molecular Sciences. 2021; 22(6):3186.

Chicago/Turabian Style

González Muñoz, Teresa; Amaral, Ana T.; Puerto-Camacho, Pilar; Peinado, Héctor; de Álava, Enrique. 2021. "Endoglin in the Spotlight to Treat Cancer" Int. J. Mol. Sci. 22, no. 6: 3186.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop